MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2022009230

Медицинская библиотека · Blood advances · 2023

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.

Shapiro Amy D, Kulkarni Roshni, Ragni Margaret V, Chambost Hervé, Mahlangu Johnny, Oldenburg Johannes, Nolan Beatrice, Ozelo Margareth C, Foster Meredith C, Willemze Annemieke, Barnowski Christopher, Jain Nisha, Winding Bent, Dumont Jennifer, Lethagen Stefan, Barnes Chris, Pasi K John

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Long-term efficacy and safety of the extended half-life recombinant factor IX Fc fusion protein (rFIXFc) has been established among previously treated patients with severe hemophilia B in 2 phase 3 trials (B-LONG [#NCT01027364] and Kids B-LONG [#NCT01440946]) and a long-term extension study (B-YOND [#NCT01425723]). In this study, we report post hoc analyses of pooled longitudinal data for up to 6.5 years for rFIXFc prophylaxis. In the B-LONG study, subjects ≥12 years received weekly dose-adjusted prophylaxis (WP; starting dose, 50 IU/kg), individualized interval-adjusted prophylaxis (IP; initially, 100 IU/kg every 10 days), or on-demand dosing. In the Kids B-LONG study, subjects <12 years received 50 to 60 IU/kg every 7 days, adjusted as needed. In the B-YOND study, subjects received WP (20-100 IU/kg every 7 days), IP (100 IU/kg every 8-16 days), modified prophylaxis, or on-demand dosing; switching between treatment groups was permitted. A total of 123 subjects from B-LONG and 30 from Kids B-LONG study were included, of whom 93 and 27, respectively, enrolled in the B-YOND study. The median cumulative duration of treatment was 3.63 years (range, 0.003-6.48 years) in B-LONG/B-YOND and 2.88 years (range, 0.30-4.80 years) in Kids B-LONG/B-YOND group. Annualized bleed rates (ABRs) remained low, annualized factor consumption remained stable, and adherence remained high throughout treatment. Low ABRs were also maintained in subjects with dosing intervals ≥14 days or with target joints at baseline. Complete resolution of evaluable target joints and no recurrence in 90.2% of baseline target joints during follow-up were observed. rFIXFc prophylaxis was associated with sustained clinical benefits, including long-term bleed prevention and target joint resolution, for severe hemophilia B.

Для цитирования: Shapiro Amy D, Kulkarni Roshni, Ragni Margaret V, Chambost Hervé, Mahlangu Johnny, Oldenburg Johannes, Nolan Beatrice, Ozelo Margareth C, Foster Meredith C, Willemze Annemieke, Barnowski Christopher, Jain Nisha, Winding Bent, Dumont Jennifer, Lethagen Stefan, Barnes Chris, Pasi K John. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.. Blood advances. 2023. DOI: 10.1182/bloodadvances.2022009230.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.